A Novel In Vitro Assay Correlates Insulin Receptor Autoantibodies With Fasting Insulin in Type B Insulin Resistance
Authors' conclusion
Quantification of InsR-aAb from serum samples via the novel in vitro assay enables identification of TBIR and monitoring of successful therapy.
Study context
- Population
- Patients with type B insulin resistance (TBIR) at the National Institutes of Health
- Outcome
- InsR-aAb bridge-assay performance and associations
Methodological detailslongitudinal serum samples, bridge-assay, Bridge-assay using recombinant human insulin receptor as bait and detector; monoclonal antibodies as positive controls for validation
- Longitudinal serum samples
- Bridge-assay
- Bridge-assay using recombinant human insulin receptor as bait and detector; monoclonal antibodies as positive controls for validation
Main finding
As reported in the abstract
- Assay was sensitive, robust and passed quality control
- Measured InsR-aAb associated with disease severity
- InsR-aAb decreased on treatment
- InsR-aAb inhibited insulin signaling in vitro
- InsR-aAb titers correlated positively with fasting insulin
Original publication
A Novel In Vitro Assay Correlates Insulin Receptor Autoantibodies With Fasting Insulin in Type B Insulin Resistance. J Clin Endocrinol Metab. Published 3 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →